Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that can affect multiple parts of the body. In 2023, it was estimated that around 500,000 individuals in the United States were living with SLE, as per DelveInsight analysis. The prevalence is significantly higher in females, who account for over 90% of all cases. Among treated SLE patients in 2023, approximately 40% experienced relapse or became refractory to first-line therapy. Currently, the biologics approved by the US FDA as adjunct SLE drugs for patients are BENLYSTA and SAPHNELO. In contrast, the use of rituximab for treating SLE is considered off-label.
7 Emerging SLE Drugs in Late-s...
